Diphenylpyraline: Difference between revisions
Brian Blank (talk | contribs) No edit summary |
No edit summary |
||
(3 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| verifiedrevid = 460792611 | |||
| IUPAC_name = 4-benzhydryloxy-1-methyl-piperidine | | IUPAC_name = 4-benzhydryloxy-1-methyl-piperidine | ||
| image = | | image = Diphenylpyraline.png | ||
| | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|international|diphenylpyraline}} | |||
| pregnancy_category = | |||
| legal_status = Rx-only | |||
| routes_of_administration = [[Mouth|Oral]], [[Topical]] | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = | |||
| metabolism = | |||
| elimination_half-life = 24-40 hours<ref name="pmid4156058">{{cite journal | author = Graham G, Bolt AG | title = Half-life of diphenylpyraline in man | journal = Journal of Pharmacokinetics and Biopharmaceutics | volume = 2 | issue = 3 | pages = 191–5 |date=June 1974 | pmid = 4156058 | doi = 10.1007/BF01059761 | url = }}</ref> | |||
| excretion = | |||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite|correct|CAS}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 147-20-6 | | CAS_number = 147-20-6 | ||
| ATC_prefix = R06 | | ATC_prefix = R06 | ||
| ATC_suffix = AA07 | | ATC_suffix = AA07 | ||
| PubChem = 3103 | | PubChem = 3103 | ||
| DrugBank = | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| C=19 | H=23 | N=1 | O=1 | | DrugBank = DB01146 | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 2992 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = 33361OE3AV | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D07862 | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 59788 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 1492 | |||
<!--Chemical data--> | |||
| C=19 | H=23 | N=1 | O=1 | |||
| molecular_weight = 281.392 g/mol | | molecular_weight = 281.392 g/mol | ||
| | | smiles = O(C(c1ccccc1)c2ccccc2)C3CCN(C)CC3 | ||
| | | InChI = 1/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 | ||
| | | InChIKey = OWQUZNMMYNAXSL-UHFFFAOYAE | ||
| | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChI = 1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 | ||
| | | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | ||
| StdInChIKey = OWQUZNMMYNAXSL-UHFFFAOYSA-N | |||
| synonyms = 4-(diphenylmethoxy)-1-methyl-piperidine | |||
| | |||
| | |||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Diphenylpyraline''' ('''DPP'''; sold as '''Allergen''', '''Arbid''', '''Belfene''', '''Diafen''', '''Hispril''', '''Histyn''', '''Lergobine''', '''Lyssipol''', '''Mepiben''', '''Neargal''') is a [[first-generation antihistamine]] with [[anticholinergic]] effects of the [[benzhydryl|diphenyl]][[piperidine]] class.<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | url = http://books.google.com/?id=5GpcTQD_L2oC&lpg=PA358&dq=Diphenylpyraline&pg=PA358#v=onepage&q}}</ref><ref name="pmid14039">{{cite journal | author = Puhakka H, Rantanen T, Virolainen E | title = Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis | journal = J Int Med Res | volume = 5 | issue = 1 | pages = 37–41 | year = 1977 | pmid = 14039}}</ref><ref name="pmid2884340">{{cite journal | author = Kubo N, Shirakawa O, Kuno T, Tanaka C | title = Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay | journal = Japanese Journal of Pharmacology | volume = 43 | issue = 3 | pages = 277–82 |date=March 1987 | pmid = 2884340 | doi = 10.1254/jjp.43.277| url = }}</ref> It is marketed in [[Europe]] for the treatment of [[allergy|allergies]].<ref name="isbn3-88763-075-0" /><ref name="pmid14039" /><ref name="isbn0-444-52166-6">{{cite book | author = Hruby, Victor J.; Ruben Vardanyan; Vardanyan, ۊRuben | title = Synthesis of essential drugs | publisher = Elsevier | location = Amsterdam | year = 2006 | pages = | isbn = 0-444-52166-6 | oclc = | doi = | url = http://books.google.com/?id=Jjc7KYWZdOYC&lpg=PA230&dq=Diphenylpyraline&pg=PA230#v=onepage&q}}</ref> DPP has also been found to act as a [[dopamine reuptake inhibitor]] and produces [[hyperactivity]] in rodents.<ref name="pmid15627433">{{cite journal | author = Lapa G, Mathews T, Harp J, Budygin E, Jones S | title = Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties | journal = Eur J Pharmacol | volume = 506 | issue = 3 | pages = 237–40 | year = 2005 | pmid = 15627433 | doi = 10.1016/j.ejphar.2004.11.017}}</ref> It has been shown to be useful in the treatment of [[Parkinsonism]].<ref name="pmid11137513">{{cite journal | author = Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I | title = Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients | journal = J Neurol Sci | volume = 182 | issue = 2 | pages = 95–7 | year = 2001 | pmid = 11137513 | doi = 10.1016/S0022-510X(00)00441-X}}</ref> | |||
==Chemistry== | |||
Diphenylpyraline, 4-diphenylmethoxy-1-methylpiperidine, is synthesized by alkylating 4-hydroxy-1-methylpiperidine with benzhydrylbromide. | |||
[[File:Diphenylpyraline synthesis.png|none|left|500px]] | |||
== See also == | |||
== | * [[Benzatropine]] | ||
* [[Desoxypipradrol]] | |||
* [[Pipradrol]] | |||
== | == References == | ||
{{Reflist|2}} | |||
{{Antihistamines}} | {{Antihistamines}} | ||
{{Stimulants}} | |||
{{ | |||
[[Category:H1 receptor antagonists]] | [[Category:H1 receptor antagonists]] | ||
[[Category:Piperidines]] | |||
[[Category:Ethers]] | |||
[[Category:Stimulants]] | |||
[[Category:Drug]] |
Latest revision as of 17:26, 10 April 2015
![]() | |
Clinical data | |
---|---|
Synonyms | 4-(diphenylmethoxy)-1-methyl-piperidine |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, Topical |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 24-40 hours[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C19H23NO |
Molar mass | 281.392 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Diphenylpyraline |
Articles |
---|
Most recent articles on Diphenylpyraline Most cited articles on Diphenylpyraline |
Media |
Powerpoint slides on Diphenylpyraline |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Diphenylpyraline at Clinical Trials.gov Trial results on Diphenylpyraline Clinical Trials on Diphenylpyraline at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Diphenylpyraline NICE Guidance on Diphenylpyraline
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Diphenylpyraline Discussion groups on Diphenylpyraline Patient Handouts on Diphenylpyraline Directions to Hospitals Treating Diphenylpyraline Risk calculators and risk factors for Diphenylpyraline
|
Healthcare Provider Resources |
Causes & Risk Factors for Diphenylpyraline |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenylpiperidine class.[2][3][4] It is marketed in Europe for the treatment of allergies.[2][3][5] DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents.[6] It has been shown to be useful in the treatment of Parkinsonism.[7]
Chemistry
Diphenylpyraline, 4-diphenylmethoxy-1-methylpiperidine, is synthesized by alkylating 4-hydroxy-1-methylpiperidine with benzhydrylbromide.
![](/images/4/4c/Diphenylpyraline_synthesis.png)
See also
References
- ↑ Graham G, Bolt AG (June 1974). "Half-life of diphenylpyraline in man". Journal of Pharmacokinetics and Biopharmaceutics. 2 (3): 191–5. doi:10.1007/BF01059761. PMID 4156058.
- ↑ 2.0 2.1 Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
- ↑ 3.0 3.1 Puhakka H, Rantanen T, Virolainen E (1977). "Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis". J Int Med Res. 5 (1): 37–41. PMID 14039.
- ↑ Kubo N, Shirakawa O, Kuno T, Tanaka C (March 1987). "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay". Japanese Journal of Pharmacology. 43 (3): 277–82. doi:10.1254/jjp.43.277. PMID 2884340.
- ↑ Hruby, Victor J.; Ruben Vardanyan; Vardanyan, ۊRuben (2006). Synthesis of essential drugs. Amsterdam: Elsevier. ISBN 0-444-52166-6.
- ↑ Lapa G, Mathews T, Harp J, Budygin E, Jones S (2005). "Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties". Eur J Pharmacol. 506 (3): 237–40. doi:10.1016/j.ejphar.2004.11.017. PMID 15627433.
- ↑ Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001). "Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients". J Neurol Sci. 182 (2): 95–7. doi:10.1016/S0022-510X(00)00441-X. PMID 11137513.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- H1 receptor antagonists
- Piperidines
- Ethers
- Stimulants
- Drug